The reality of this capital structure is stark: existing Processa retail and institutional shareholders have been virtually wiped out in terms of percentage ownership. They have been diluted down to less than 1% of the combined entity (Pulse 2.0). However, in exchange for relinquishing control, legacy shareholders are now tied to a heavily funded entity with an elite institutional backing, escaping the imminent threat of bankruptcy that loomed in 2025. Unsurprisingly, the market reaction to this extreme dilution was initially violent, with PCSA stock plummeting 33.44% during the July 29 trading session when the deal was announced (StockTitan).
A History of Punitive Reverse Stock Splits
Compounding the pain for long-term legacy shareholders is Processa's reliance on reverse stock splits to maintain compliance with Nasdaq's $1.00 minimum bid price requirement. January 2024: Processa executed a 1-for-20 reverse stock split, reducing outstanding shares from approximately 24.6 million to 1.2 million (Processa SEC Filings). December 2025: Facing renewed delisting threats, the company executed an even more severe 1-for-25 reverse stock split, effective December 17, 2025. This action consolidated every 25 existing shares into one new share, leaving the total authorized shares unchanged at 1 billion, providing the company massive headroom to issue new equity—headroom it subsequently utilized for the Vidya acquisition (Investing.com).
A legacy investor holding 500 shares in December 2023 would hold exactly 1 share by January 2026, and that single share now represents less than 1% of the newly formed company's equity base.
Insider Activity and Alignment
Despite the historical destruction of shareholder value, recent insider activity signals a strong internal conviction regarding the Vidya transaction. Executive compensation has been rapidly aligned with the new structure. CFO Equity Grants: Following the deal in late July 2026, CFO Russell Skibsted received a grant of 11,883 Restricted Stock Units (RSUS) and stock options covering 12,960 common shares at an exercise price of $4.96. The RSUs feature a deferred-settlement mechanism, distributing shares only upon termination, a six-month anniversary, change of control, or death (StockTitan). CEO Purchases and Conversions: In May 2026, CEO George K. Ng made multiple open-market purchases (totaling nearly 4,000 shares) at prices ranging from $2.69 to $2.97. In August 2026, he reported the conversion of 1,600 shares of restricted stock into common stock, maintaining significant direct and indirect holdings, alongside options to acquire 30,720 shares at $4.96 (StockTitan). Vidya's Founder and Executive Chair, Dr. Sheila Gujrathi, has been appointed to Processa's Board of Directors, ensuring continuity of leadership over the VT-7208 asset (Pulse 2.0).
Clinical Pipeline Deep Dive: The VT-7208 Asset
The sole fundamental driver of Processa's future valuation is VT-7208, the lead asset acquired from Vidya Therapeutics. VT-7208 is a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases.
The Mechanics of BTK Inhibition
Bruton's tyrosine kinase is an essential enzyme in the signaling pathway of B cells and myeloid cells. When BTK is activated, it triggers mast cell degranulation—the rapid release of histamines and other inflammatory mediators that cause allergic reactions and severe hives. It also drives B cell-mediated autoantibody production, which is implicated in severe neurological and autoimmune disorders.
Early-generation BTK inhibitors revolutionized the treatment of certain B-cell malignancies (cancers) but suffered from significant off-target toxicities, particularly severe liver injury and cardiovascular events, limiting their broad application in non-oncology autoimmune conditions. For example, in 2022 and 2023, the FDA was forced to place partial clinical holds on several prominent late-stage BTK inhibitors, including Merck's evobrutinib, Sanofi's tolebrutinib, and Biogen/InnoCare's orelabrutinib, specifically due to dangerous instances of drug-induced liver injury (elevated liver enzymes) observed in multiple sclerosis trials (pharmaphorum.com).
The VT-7208 Value Proposition
Vidya Therapeutics designed VT-7208 as a "next-generation," potentially best-in-class, CNS-penetrant, covalent BTK inhibitor. Its specialized selectivity profile is intended to overcome the efficacy and safety limitations of earlier BTK drugs, specifically minimizing the hepatotoxicity that hobbled evobrutinib and tolebrutinib (Processa Investor Relations).
Crucially, the drug is orally administered (once-daily) and is CNS-penetrant—meaning it can cross the blood-brain barrier. This unique pharmacokinetic profile allows it to operate in both peripheral immunology and central neurology. A completed Phase 1/2, randomized, double-blind, placebo-controlled, single and multiple dose escalation study evaluated VT-7208 initially in healthy participants, followed by an expansion cohort in adult patients with Multiple Sclerosis (Synapse). This study, originally advanced by Vidya Therapeutics prior to the acquisition, demonstrated sustained target engagement in both the cerebrospinal fluid and the rest of the body (Pulse 2.0). The drug was generally well-tolerated with no serious adverse events observed, suggesting it could be administered effectively at lower doses than competing drugs (Fierce Biotech).
Three Parallel Phase 2 Programs
The influx of $200 million in PIPE capital completely reshapes the development timeline for VT-7208. Rather than advancing indications sequentially—a capital-preservation strategy standard for underfunded biotechs—Processa will run three Phase 2 proof-of-concept studies in parallel starting in late 2026/early 2027: 1. Food Allergy (Immunology): Targeting patients with severe, life-threatening food allergies. 2. Chronic Spontaneous Urticaria (CSU): A debilitating skin condition characterized by persistent, itchy hives with no known external trigger. The FDA recently approved Novartis' Rhapsido as the first BTK inhibitor for CSU, validating the biological pathway but leaving a massive market opening for a safer, next-generation competitor (Fierce Biotech). 3. Relapsing Multiple Sclerosis (RMS): A chronic neurological disease. VT-7208's ability to cross the blood-brain barrier is critical here, addressing an area of exceptionally high unmet clinical need.
Initial Phase 2 data readouts for these programs are highly anticipated in the second half of 2027 (Food Allergy), the first half of 2028 (CSU), and the second half of 2028 (RMS).